Individuals with chronic asthma show evidence of structural remodel ing of the airways, including accumulation of extracellular matrix proteins such as collagen and thickening of smooth muscle. Current therapies for asthma are beneficial in controlling symptoms and airway inflammation but have little effect on lung remodeling. For example, in bronchial biopsies from individuals with asthma similar levels of subepithelial fibrosis are seen after antiinflammatory therapy with corticosteroids 1,2 , suggesting that the mechanisms that regulate remodeling may be distinct from those that induce eosinophilia or other aspects of lung inflammation. The severity of asthma and level of lung function impairment are also associated with increased mass of peribronchial smooth muscle 3 . It has been suggested that airway remodeling is the result of a complex interplay between immune cells and these structural cells, driven by a network of cytokines and growth factors, notably TGFβ and IL13 (refs. 4, 5) . Many of these soluble mediators are involved in immune responses as well as tissue repair. Thus, new targets for airway remodeling are needed for the development of therapeutics for diseases of the lung, including asthma.
Individuals with chronic asthma show evidence of structural remodel ing of the airways, including accumulation of extracellular matrix proteins such as collagen and thickening of smooth muscle. Current therapies for asthma are beneficial in controlling symptoms and airway inflammation but have little effect on lung remodeling. For example, in bronchial biopsies from individuals with asthma similar levels of subepithelial fibrosis are seen after antiinflammatory therapy with corticosteroids 1, 2 , suggesting that the mechanisms that regulate remodeling may be distinct from those that induce eosinophilia or other aspects of lung inflammation. The severity of asthma and level of lung function impairment are also associated with increased mass of peribronchial smooth muscle 3 . It has been suggested that airway remodeling is the result of a complex interplay between immune cells and these structural cells, driven by a network of cytokines and growth factors, notably TGFβ and IL13 (refs. 4,5) . Many of these soluble mediators are involved in immune responses as well as tissue repair. Thus, new targets for airway remodeling are needed for the development of therapeutics for diseases of the lung, including asthma.
The TNF superfamily consists of many membranebound and soluble proteins with proinflammatory effects on innate and adap tive immune responses. The TNF family ligand LIGHT (TNFSF14; homologous to lymphotoxins, shows inducible expression, com petes with HSV glycoprotein D for HVEM, a receptor expressed by T lymphocytes), is a homotrimer expressed on the surface of several immune cells. LIGHT binds the herpesvirus entry mediator (HVEM; TNFRSF14) and also is a shared ligand with membrane lymphotoxin (LTαβ) for LTβR 6, 7 . As other TNF superfamily members are being recognized as key mediators in asthmatic inflammation, including OX40 ligand (TNFSF4) 8, 9 , as well as TNF itself 10 , we hypothesized that LIGHT might be involved in driving aspects of lung inflammation or have a role in airway remodeling. In line with this, a recent report found that sputum LIGHT levels in people with asthma correlated with decreased lung function 11 . Using two mouse models of chronic asthma and a therapeutic blocking strategy, we now show a role for LIGHT in controlling the extent of airway remodeling with resultant regulation of the proremodeling cytokines IL13 and TGFβ.
RESULTS

Blockade of LIGHT or LTab reduces airway remodeling
We used a model of house dust mite (HDM)induced chronic asthma to test the effects of blocking the interactions of LIGHT or LTαβ with HVEM and LTβR. Wildtype (WT) mice develop acute airway inflam mation after three challenges with HDM extract 12 and then undergo a fibrotic response in the lung, together with other structural changes reminiscent of those found in human asthma, when challenges are extended to twice per week for several weeks. We used a fusion protein of Fc with the extracellular portion of the lymphotoxin β receptor (LTβRFc) that can prevent LIGHTLTβR, LIGHTHVEM and LTαβ LTβR interactions 13 . We administered LTβRFc after development of acute airway inflammation, 24 h before each additional intranasal HDM challenge (Fig. 1a) . Both increased peribronchial smooth muscle area and lung fibrosis were induced in control mice after chronic HDM exposure (Fig. 1b,c) , but mice receiving LTβRFc showed much less fibrosis, as measured by peribronchial trichrome staining 14 , airway collagen1 expression and assays for total lung collagen (Fig. 1b) . αsmooth muscle actin expression was also significantly lower in the LTβRFc-treated mice ( Fig. 1c and Supplementary Fig. 1) .
We next performed invasive pulmonary function testing. After exposure to nebulized methacholine, mice treated with LTβRFc had reduced airway hyperresponsiveness (AHR) as compared with IgG treated mice (Fig. 1d) . We also found a decrease in baseline airway resistance (Fig. 1d) , which is probably related to the reduction in peribronchial smooth muscle and airway fibrosis 15 . Bronchoalveolar lavage fluid (BALF) eosinophil numbers, and the overall extent of peribronchial cellular infiltrates scored by lung histology, were similar in both LTβRFc and control IgG groups (Supplementary Fig. 2a ). BALF neutrophil, B cell and CD4 + and CD8 + T lymphocyte numbers in the lung, and the number of bronchial epithelial cells staining for mucus (periodic acid-Schiff), were not significantly different after LTβRFc treatment (Supplementary Fig. 2 ). Thus, we found the reduction in remodeling features and AHR after LTβRFc treatment were independent of effects on airway eosinophilia and histological infiltration detected after chronic allergen challenge.
LIGHT is required for airway remodeling LIGHT expression was induced on lung CD45 + cells after acute HDM challenge (Supplementary Fig. 3 ). We found LIGHT on B and T cells but not macrophages or granulocytes. To directly investigate the role of LIGHT, we subjected LIGHTdeficient (Tnfsf14 −/− ) mice 16 to the chronic HDM protocol. Similarly to mice treated with LTβRFc, Tnfsf14 −/− mice had reduced peribronchial fibrosis, collagen1 and αsmooth muscle actin expression, total lung collagen abundance (Fig. 2a,b) , and showed reduced AHR as compared with WT mice (Fig. 2c) . LIGHT deficient mice had only a modest reduction in lung inflammatory infiltrates, as determined by histologic scoring, and no statistical differ ence in airway eosinophilia (Supplementary Fig. 4) .
Because there is no reagent that can specifically block the inter action of LIGHT with HVEM and LTβR without affecting LTαβLTβR interactions, we treated Tnfsf14 −/− mice with LTβRFc to determine whether LTαβ is active in the absence of LIGHT. LTβRFc-and control IgG-treated Tnfsf14 −/− mice had similar fibrosis and smooth muscle hyperplasia (Supplementary Fig. 5a ,b) and no difference in AHR (Supplementary Fig. 5c ). Although LTαβ and LIGHT could act sequentially, the data from the LIGHTdeficient mice suggests that LIGHT is the primary mediator of the remodeling process.
To confirm our findings in another model, we used ovalbumin (OVA) as the antigen for sensitization and chronic repetitive airway challenges. Mice treated with LTβRFc after acute inflammation was established had a strong reduction of induced fibrosis and smooth muscle actin expression (Supplementary Fig. 6 ). Scoring revealed only a modest reduction of inflammatory lung infiltrates, and air way eosinophilia was not different in LTβRFc-treated or Tnfsf14 −/− mice compared to controls (Supplementary Fig. 7) . Thus, LIGHT is crucial for the induction of airway remodeling in both HDM and OVAinduced chronic asthma models.
LIGHT regulates lung TGF-b
Studies of human and mouse cells have suggested that TGFβ is a principle mediator of airway remodeling, and its expression is elevated in lung samples from individuals with asthma 5 . TGFβ can induce epithelialmesenchymal transition (EMT), differentiation of myofibroblasts, production of extracellular matrix proteins, includ ing collagen1, and smooth muscle cell proliferation 5, 17 . We detected a significantly increased concentration of lung TGFβ1 after chronic HDM or OVA challenges (Fig. 3a) . However, significantly less free TGFβ1 was expressed in lung homogenates from WT C57BL/6 mice treated with LTβRFc, or from Tnfsf14 −/− mice (Fig. 3a) .
Several cell types might produce TGFβ1 in the lung and be targets of LIGHT. Immunohistochemistry revealed strong expression of LTβR in cells close to the subepithelial region, where smooth muscle hyperplasia and fibrosis occur during airway remodeling (Fig. 3b) . This was consistent with the normal location of lung macrophages. Flow cytometry analysis revealed a population of cells expressing CD11c and Mac3 that also strongly expressed LTβR (Fig. 3c) . Further characterization confirmed that these were macrophages coexpressing Induced reflects levels above those detected in mice receiving three intranasal challenges before LTβR-Fc treatment. (d) Peak airway resistance with increasing doses of methacholine and baseline resistance without methacholine exposure (six or seven mice per group). *P < 0.05, **P < 0.005, ***P < 0.001, ****P < 0.0001, means ± s.e.m., Mann-Whitney test. Data are from two or three independent experiments. Scale bars, 100 µm. Fig. 8 ) 18, 19 . Macrophages have been implicated in many lung remodeling diseases, including asthma, chronic obstructive pulmonary disease and hypersensitivity pneumo nitis [20] [21] [22] , and it has been suggested that they promote remodeling through production of TGFβ 23 .
We found that LIGHTdeficient mice had reduced percentages and absolute numbers of lung macrophages after chronic challenge with either HDM or OVA (Fig. 3d) . TGFβ is initially complexed with latencyassociated peptide (LAP), and LAP expression correlates with TGFβ production in many cell types [24] [25] [26] , including macrophages 27 . and resistance after challenge with 48 mg ml −1 methacholine (means ± s.e.m., Mann-Whitney test from six or seven mice per group). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Scale bars, 100 µm. concentrations assessed in lung homogenates from WT mice treated as in Figure 1 (data from six to eight mice per group; acute signifies levels before immunoglobulin treatment; levels of two naive mice also shown, means ± s.e.m., Mann-Whitney, *P < 0.03); WT and Tnfsf14 −/− mice treated as in Figure 2 (data from three or four mice per group, means ± s.e.m., t test, *P < 0.02); WT mice treated as in Supplementary Figure 6 (data from four pooled mice per group run in duplicate, mean ± s.e.m., except single IgG group); WT and Tnfsf14 −/− mice treated as in Supplementary Figure 6 (data from four pooled mice per group run in quadruplicate, means ± s.e.m., t test, *P < 0.01). Immunofluorescent staining of lung sections from chronically chal lenged mice revealed that LAP was expressed predominantly on Mac3 + cells, in addition to airway epithelium, further suggesting that macro phages are a major source of LAP and TGFβ in the remodeled lung (Fig. 3e) . Notably, treatment of chronically challenged WT mice with LTβRFc led to a strong reduction in the percentages and total numbers of LAP + macrophages (Fig. 3f) , and LIGHTdeficient mice also had a lower proportion of these cells after challenge (Fig. 3f) . This implies that LIGHT regulates macrophage accumulation in the lung and directly or indirectly regulates the number of TGFβ-producing cells.
LTbR signaling induces fibrosis and macrophage TGF-b
As LTβR was expressed on lung macrophages, we tested whether LTβR signaling could induce remodeling. We sensitized and challenged WT mice with OVA, followed by injection of agonist antibody to LTβR 13 given two times per week for 2 weeks, but without further antigen chal lenge. Mice receiving the agonist antibody showed a marked induction of fibrosis above the level found in acutely challenged mice (Fig. 4a) . Furthermore, there was a doubling in the number of LAP + lung macro phages in the agonist group (Fig. 4a) .
We then purified naive lung macrophages and cultured them with agonist antibody to LTβR. Macrophage LAP expression and TGFβ1 mRNA levels increased after stimulation of the LTβR (Fig. 4b,c) . The concentration of free TGFβ1 in the culture supernatant did not increase (data not shown), but when HDM was added, LTβR stimulation signif icantly increased release of TGFβ1 (Fig. 4c) . This is probably related to a requirement for were stained for trichrome (top row, scale bar, 100 µm), collagen-1 (second row, scale bar, 100 µm), α-smooth muscle actin (third row, scale bar, 50 µm) and scored for fibrosis and smooth muscle area (bottom row, 40 airways per group, means ± s.e.m., Mann-Whitney, *P < 0.05, **P < 0.005). WT mice primed with HDM over 3 weeks were treated with intranasal rLIGHT or PBS given eight times over 2 weeks (a) or pCDNA3 mouse LIGHT plasmid or control plasmid given four times over 2 weeks (b). Antibody to TGF-β (anti-TGF) or isotype control IgG was also injected as indicated. Induced reflects levels above those detected in lungs of mice receiving PBS (a) or control plasmid (b). A, airway; BV, blood vessel.
an inflammatory signal for proteolytic release of active TGFβ1 from LAP. Additionally, stimulation of LTβR on sorted LAP − macrophages resulted in direct upregulation of surface LAP (Fig. 4d) . We also cul tured purified lung macrophages with soluble recombinant LIGHT (rLIGHT) (Fig. 4e) in the presence or absence of an inhibitor of extra cellular signal-regulated kinase (ERK; U0126), a kinase previously shown to regulate TGFβ production from macrophages 27 . LIGHT stimulation increased expression of intracellular TGFβ, and ERK inhibition completely abrogated TGFβ induction (Fig. 4e) . Together, these results suggest that one mechanism by which LIGHT can pro mote fibrosis is through direct stimulation of LTβR on lung macro phages, resulting in both increased accumulation of these cells in the lung and increased TGFβ expression.
LIGHT directly induces airway remodeling dependent on TGF-b
To test whether LIGHT can directly induce airway fibrosis and smooth muscle hyperplasia in vivo by a TGFβ-dependent mecha nism, we established acute lung inflammation in WT mice with intra nasal HDM given once per week for 3 weeks. This was then followed by intranasal administration of recombinant LIGHT given eight times over the next 2 weeks (in the absence of antigen). Mice that received rLIGHT developed airway fibrosis and smooth muscle hyperplasia compared with those that received PBS, which was reduced by TGFβ blockade (Fig. 5a) . To confirm this, we challenged mice with the same acute HDM protocol followed by intranasal administration of a plasmid vector encoding mouse LIGHT. Similarly, these mice showed marked fibrosis and smooth muscle hyperplasia, which we did not observe in mice receiving an empty vector (Fig. 5b) . These features were also suppressed by blocking TGFβ. Thus, LIGHT can induce remodeling in the airway, and this process is partly dependent on TGFβ.
LIGHT regulates lung IL-13 IL13 is also a pleiotropic regulator of lung remodeling, inducing some activities similarly to TGFβ 4 . IL13 is elevated in lung samples with remodeling from individuals with asthma 28, 29 and can induce epithelial cell proliferation 30 , myofibroblast proliferation and smooth muscle actin expression 31 . Furthermore, TGFβ and IL13 can act synergistically to induce features of asthmatic remodeling 32, 33 . The concentration of IL13 was decreased by 50% in lung homogenates from HDMchallenged, LIGHTdeficient mice, as well as from those treated therapeutically with LTβRFc (Fig. 6a) . We found a smaller, but significant, decrease in OVAchallenged mice that lacked LIGHT or were treated with LTβRFc (Fig. 6a) . T helper type 2 (T H 2) cells might be a source of IL13 (ref. 4 ) and a potential target of LIGHT activity. T cells express HVEM, but not LTβR, and HVEM signals can increase proliferation and cytokine secretion from T cells to augment their response to anti gen 7 . However, we did not detect differences in the numbers of T H 2 cells in the airway or lung of Tnfsf14 −/− mice or after LTβRFc treat ment in WT mice (Supplementary Fig. 9a) . Additionally, CD4 + T cell production of IL13 and IL5 was unaltered in comparison with controls ( Supplementary Fig. 9b,c) , indicating that LIGHT does not regulate T H 2 cells during chronic repetitive allergen challenges.
Other cell types that might be a source of IL13 include eosinophils, mast cells and structural cells 4 . Because binding of LIGHT to HVEM increases cytokine production in granulocytes in vitro 34 , we rea soned that HVEM might be expressed on eosinophils. Indeed, sorted BALF eosinophils (>95% of sorted granulocytes) from acute OVA or HDMchallenged mice expressed HVEM but not LTβR (Fig. 6b and  data not shown) . We then performed intracellular cytokine stain ing for IL13 in eosinophils from WT mice after sensitization and chronic challenge with HDM or OVA (Fig. 6c) . Lung CD45 + CD11c − granulocytes were predominantly eosinophils and constitutively expressed intracellular IL13, which suggests these were highly dif ferentiated cells at the end of the chronic antigen challenge (Fig. 6c) . In contrast, those obtained from mice receiving LTβRFc or LIGHT deficient mice had reduced IL13 expression (Fig. 6c) . To directly test the effect of LIGHT, we cultured less differentiated eosinophils isolated from the lung and BALF of antigensensitized WT mice that Figure 6 LIGHT promotes IL-13 production by lung eosinophils. (a) IL-13 content in mice primed and challenged with HDM or OVA. Lung homogenates from mice treated as in Figures 1 and 2 and Supplementary  Figure 6 were analyzed (five to seven mice per group from Figure 1 , three or four mice per group from Figure 2 and triplicates of pooled samples from four to seven mice per group from Supplementary Figure 6 , means ± s.e.m., t test, *P < 0.05, **P < 0.01, ***P < 0.005). (b) Flow cytometry analysis of sorted granulocytes (>95% eosinophils by cytospin, bottom; scale bar, 50 µm) from WT mice after acute intranasal OVA challenge for LTβR (top middle) and HVEM expression (top right). Isotype control in gray. (c) Flow cytometry analysis of CD45 + CD11c − granulocyte-gated lung eosinophils (top and bottom left) from mice in Supplementary Figure 6 for intracellular IL-13 directly ex vivo (middle right). Siglec-F + CD11c − eosinophils from mice in Figure 1 had received only two intranasal antigen challenges. In this case, the eosinophils did not spontaneously produce IL13, but IL13 expression was strongly promoted by stimulation with rLIGHT (Fig. 6d) . In contrast, the gated lymphocyte population in these cultures showed minimal induction of IL13 after LIGHT stimula tion (Supplementary Fig. 10 ). Collectively, these data indicate that LIGHT is required in models of chronic asthma for maximal expres sion of two of the primary cytokines thought to promote airway remodeling, and that LIGHTLTβR or LIGHTHVEM interactions promote proremodeling activities of lung macrophages and lung eosinophils, two of the cell types associated with chronic asthma and remodeling in humans.
DISCUSSION
We show that LIGHT is crucial for airway remodeling and air way hyperresponsiveness in two mouse models of chronic asthma. Notably, our data present a new role for this molecule in lung remodel ing and fibrotic disease and suggest LIGHT may be a relevant target for suppressing fibrosis and smooth muscle hyperplasia. Several pub lished reports confirm an association of LIGHT with elements of tissue remodeling. In individuals with scleroderma, a disease that can lead to pulmonary fibrosis, BALF concentrations of LIGHT were higher in those with lung involvement compared to those with only nonpulmonary manifestations 35 . Moreover, a first report evaluating LIGHT expression in individuals with asthma was recently pub lished 11 . The authors measured soluble LIGHT in the sputum of a heterogeneous group of 242 people with asthma, including 48 with severe asthma. After analysis of approximately 40 soluble mediators, only LIGHT was found to inversely correlate with lung function, as assessed by baseline forced expiratory volume in one second (that is, higher LIGHT levels were associated with lower baseline forced expiratory volumes, or lung function). As LIGHT has two receptors, targeting its interaction with LTβR and HVEM may prevent multiple proremodeling activities during the development of chronic asthma. We identified TGFβ as being regu lated by LIGHT and found that lung macrophages expressing LTβR are responsive to LIGHT. Of note, rLIGHT has also been found to increase expression of matrix metalloproteinase9 (MMP9) in macro phages 36 . MMP9 is found in the BALF of people with asthma 37 , and MMP9-deficient mice show reduced peribronchial fibrosis after chronic allergen challenge 38 . Together with our results, these studies suggest that LIGHTLTβR interactions on lung macrophages might regulate the expression of both TGFβ and MMP9 during chronic asthma. Although TGFβ is almost universally considered to be involved in lung remodeling 5 , one report in a mouse model of chronic HDM administration found it was dispensable for driving structural changes in the lung 39 . This may be due to differences in the frequency and periodicity of HDM exposure in that study compared to our and others' studies. Other models with OVA have shown a clear role for TGFβ in airway remodeling 40, 41 , and we found TGFβ expression was reduced by targeting LIGHT in both our HDM and OVA models. This is concordant with the demonstration that direct administra tion of LIGHT via the airways induced remodeling in a TGFβ-dependent manner.
IL13 is similarly considered to have a major role in remodel ing 4 and is required for structural changes in the lungs in OVA, fungal and HDMinduced animal models [42] [43] [44] . We found LIGHT promotes IL13 expression in eosinophils and markedly impaired eosinophil IL13 production was observed after treatment with LTβRFc. The importance of eosinophils in human asthmatic remodeling has been shown after treatment with IL5-specific anti bodies, which reduces eosinophils in the lung and leads to a reduction in airway deposition of extracellular matrix proteins 45 . Eosinophils have also been shown to contribute to airway remodeling in OVA induced animal models of chronic asthma 14, 46 . One report found that eosinophils were not required for HDMdriven remodeling 47 , but with the caveat that this experimental protocol differed in dose, dura tion and frequency of challenges compared to that used here. These differences in terms of the molecules required for remodeling may simply reflect variations that might occur in humans and, rather than being contradictory, may provide key insight into subpopulations of people with asthma. Regardless of the ultimate target, or targets, of LIGHT activity, our data show that in various antigen models LIGHT is a primary orchestrator of the remodeling processes.
As well as regulating TGFβ and IL13, LIGHT may control addi tional cellular functions that contribute to remodeling. rLIGHT has been shown to enhance proliferation of vascular smooth muscle cells 48 as well as promote expression of αsmooth muscle actin 49 , actions mediated by HVEM and LTβR, respectively. Bronchial epi thelial cells may also be a target. LTβR was found on epithelial cells in human lungs 50 , and we found weak expression of LTβR in lungs of chronically challenged mice, albeit less than on macrophages. Bronchial epithelial cells can undergo EMT driven by TGFβ 5, 17 , and this might be one source of the increased smooth muscle mass characteristic of airway remodeling. However, we saw induction of fibrosis as well as increased numbers of lung macrophages after injection of an agonist antibody to LTβR without a correspond ing increase in peribronchial smooth muscle hyperplasia (data not shown). Notably, we did detect smooth muscle hyperplasia in mice receiving intranasal rLIGHT and LIGHT plasmid, suggesting that HVEM and not LTβR has a role in driving the increase in smooth muscle mass. Future studies are needed to determine whether smooth muscle cells or bronchial epithelial cells are direct targets of LIGHT activity in vivo.
Neutralizing LIGHT reduced airway hyperresponsiveness despite no robust effects on the peribronchial immune infiltrates. This is consistent with previous reports that suggest that airway hyperrespon siveness in chronically challenged mice correlates more with remod eling changes than the degree of cellular infiltrates in the lung 15, 51, 52 . The precise relationship between airway inflammation, hyperrespon siveness and remodeling in human asthmatics is unclear, but there is evidence that baseline lung function and severity of asthma is related to the smooth muscle mass 3 . The dichotomy between eosinophil accu mulation and fibrosis that we detected is also consistent with previous data that have suggested that airway remodeling may be a distinct process from eosinophilic lung inflammation 1, 2, 53, 54 . Some studies have additionally suggested that IL13 might directly contribute to the degree of hyperresponsiveness 55 , and therefore the combination of less fibrosis, smooth muscle hyperplasia and IL13 after LTβRFc treatment or in Tnfsf14 −/− mice most likely explains the relatively normal lung function we observed.
In summary, we report that the TNF family member LIGHT is essential for airway remodeling in several mouse models of chronic asthma. Blockade of LIGHT, after acute inflammation was estab lished in the lung, substantially reduced airway fibrosis and smooth muscle hyperplasia, two factors associated with a decline in lung function in human asthmatics. This previously unknown role for LIGHT in airway remodeling may lead to strategies targeting this molecule in asthmatic airway remodeling or other diseases involving fibrosis and remodeling. 
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